CUZD1

Summary

CUZD1 (CUB and zona pellucida like domains 1, HGNC:17937) is a protein-coding gene on chromosome 10q26.13, encoding CUB and zona pellucida-like domain-containing protein 1 (Q86UP6). Localized to zymogen granules, where it functions in trypsinogen activation.

Predicted to be involved in trypsinogen activation. Located in membrane.

Source: NCBI Gene 50624 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• Clinical variants (ClinVar): 79 total — 1 pathogenic
• MANE Select transcript: NM_022034

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17937
Approved symbol	CUZD1
Name	CUB and zona pellucida like domains 1
Location	10q26.13
Locus type	gene with protein product
Status	Approved
Aliases	ERG-1, UO-44
Ensembl gene	ENSG00000138161
Ensembl biotype	protein_coding
OMIM	616644
Entrez	50624

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 nonsense_mediated_decay, 2 protein_coding, 1 retained_intron

ENST00000338948, ENST00000368899, ENST00000368900, ENST00000368901, ENST00000392790, ENST00000924221

RefSeq mRNA: 1 — MANE Select: NM_022034 NM_022034

CCDS: CCDS7631

Canonical transcript exons

ENST00000392790 — 9 exons

Exon	Start	End
ENSE00003497260	122833672	122833940
ENSE00003578429	122834706	122835097
ENSE00003728879	122832158	122832450
ENSE00003841264	122839017	122839231
ENSE00003845261	122836831	122837048
ENSE00003845600	122837404	122837554
ENSE00003846972	122841178	122841328
ENSE00003848993	122845762	122845857
ENSE00003850360	122836178	122836350

Expression profiles

Bgee: expression breadth ubiquitous, 130 present calls, max score 99.82.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 5.4226 / max 9269.9978, expressed in 73 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
111766	5.3742	73
111765	0.0484	1

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	99.82	gold quality
pancreas	UBERON:0001264	98.87	gold quality
islet of Langerhans	UBERON:0000006	97.35	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	93.66	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	76.14	gold quality
granulocyte	CL:0000094	70.77	gold quality
stromal cell of endometrium	CL:0002255	65.17	gold quality
mucosa of transverse colon	UBERON:0004991	64.79	gold quality
lower esophagus mucosa	UBERON:0035834	64.56	gold quality
spleen	UBERON:0002106	64.21	gold quality
cerebellar hemisphere	UBERON:0002245	63.65	gold quality
cerebellar cortex	UBERON:0002129	63.57	gold quality
cerebellum	UBERON:0002037	63.50	gold quality
right hemisphere of cerebellum	UBERON:0014890	62.74	gold quality
lymph node	UBERON:0000029	61.56	gold quality
primary visual cortex	UBERON:0002436	61.36	gold quality
right coronary artery	UBERON:0001625	61.35	gold quality
small intestine Peyer’s patch	UBERON:0003454	60.73	gold quality
Ammon’s horn	UBERON:0001954	60.70	gold quality
ectocervix	UBERON:0012249	60.65	gold quality
pituitary gland	UBERON:0000007	60.64	gold quality
metanephros cortex	UBERON:0010533	60.05	gold quality
small intestine	UBERON:0002108	59.97	gold quality
putamen	UBERON:0001874	59.75	gold quality
adenohypophysis	UBERON:0002196	59.68	gold quality
esophagus mucosa	UBERON:0002469	59.62	gold quality
transverse colon	UBERON:0001157	59.56	gold quality
body of uterus	UBERON:0009853	59.52	gold quality
fundus of stomach	UBERON:0001160	59.15	gold quality
nucleus accumbens	UBERON:0001882	59.14	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-81547	yes	35651.47
E-MTAB-5061	yes	2247.71
E-ANND-3	yes	27.11
E-MTAB-6524	no	39.77
E-MTAB-6678	no	2.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

10 targeting CUZD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-664A-3P	99.22	71.08	2696
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-6811-5P	97.98	64.96	848
HSA-MIR-6511B-5P	97.98	65.64	823
HSA-MIR-4642	97.52	67.60	916
HSA-MIR-597-5P	96.82	67.57	732
HSA-MIR-3690	96.44	65.18	737

Literature-anchored findings (GeneRIF, showing 8)

• human UO-44 gene expression may prove to be valuable pretreatment targets for antitumor therapy (PMID:16862170)
• CUZD1 appears to be a highly promising novel serum biomarker for ovarian cancer diagnosis. (PMID:22985796)
• CUZD1 appears to be one of the relatively few biomarkers that serve as both cancer biomarker and autoantigen of autoantibodies in an autoimmune disease unrelated to cancerous organs. (Review) (PMID:23710207)
• Totals of 12.4% and 20.8% of Crohn’s disease patients were positive for IgA/IgG type of anti-GP2 and anti-CUZD1, respectively. Positivity for anti-pancreatic autoantibodies predicted a faster progression towards complicated disease course. (PMID:25968583)
• This study describes the development of tools targeting CUZD1 protein, its tissue expression pattern and levels in several biological fluids. These new tools will facilitate future investigations aiming to delineate the role of CUZD1 in physiology and pathobiology. (PMID:28746862)
• Data suggest that overexpression of CUZD1, regulator of growth factor signaling pathways controlled by PRLR and STAT5, promotes tumorigenesis in mammary epithelial cells. (CUZD1 = CUB and zona pellucida-like domain-containing protein-1; PRLR = prolactin receptor; STAT5 = signal transducer and activator of transcription-5) (PMID:29321207)
• Variants in the pancreatic CUB and zona pellucida-like domains 1 (CUZD1) gene in early-onset chronic pancreatitis - A possible new susceptibility gene. (PMID:35589511)
• Association analysis of CUZD1 variants in European chronic pancreatitis patients. (PMID:37858432)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Cuzd1	ENSMUSG00000040205
rattus_norvegicus	Cuzd1	ENSRNOG00000029945

Paralogs (35): NRXN3 (ENSG00000021645), TLL1 (ENSG00000038295), CP (ENSG00000047457), DCBLD2 (ENSG00000057019), HEPH (ENSG00000089472), TLL2 (ENSG00000095587), NRP1 (ENSG00000099250), PCOLCE (ENSG00000106333), CNTNAP3 (ENSG00000106714), CUBN (ENSG00000107611), CNTNAP1 (ENSG00000108797), NRXN2 (ENSG00000110076), MEP1A (ENSG00000112818), NRP2 (ENSG00000118257), MFGE8 (ENSG00000140545), MEP1B (ENSG00000141434), PDGFC (ENSG00000145431), CNTNAP4 (ENSG00000152910), CNTNAP3B (ENSG00000154529), CNTNAP5 (ENSG00000155052), CDCP2 (ENSG00000157211), PCOLCE2 (ENSG00000163710), EDIL3 (ENSG00000164176), NETO1 (ENSG00000166342), BMP1 (ENSG00000168487), PDGFD (ENSG00000170962), NETO2 (ENSG00000171208), CNTNAP2 (ENSG00000174469), NRXN1 (ENSG00000179915), HEPHL1 (ENSG00000181333), F8 (ENSG00000185010), ASTL (ENSG00000188886), F5 (ENSG00000198734), MFRP (ENSG00000235718), CNTNAP3C (ENSG00000283378)

Protein

Protein identifiers

CUB and zona pellucida-like domain-containing protein 1 — Q86UP6 (reviewed: Q86UP6)

Alternative names: Transmembrane protein UO-44

All UniProt accessions (3): A0A0A0MRA6, A0A0A0MRL2, Q86UP6

UniProt curated annotations — full annotation on UniProt →

Function. Localized to zymogen granules, where it functions in trypsinogen activation. May indirectly regulate cell motility, cell-cell and cell/extracellular matrix interactions.

Subcellular location. Zymogen granule membrane.

Tissue specificity. Detected in pancreas and epithelium of ovary. Expressed at higher levels in ovarian tumors than in normal tissue.

Isoforms (3)

UniProt ID	Names	Canonical?
Q86UP6-1	1, UO-44D	yes
Q86UP6-2	2, UO-44B, UO-44C
Q86UP6-3	3, UO-44A

RefSeq proteins (1): NP_071317* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000859	CUB_dom	Domain
IPR001507	ZP_dom	Domain
IPR035914	Sperma_CUB_dom_sf	Homologous_superfamily
IPR042235	ZP-C_dom	Homologous_superfamily
IPR048290	ZP_chr	Domain
IPR055355	ZP-C	Domain
IPR055356	ZP-N	Domain

Pfam: PF00100, PF00431, PF23344

UniProt features (26 total): glycosylation site 5, disulfide bond 5, sequence conflict 5, domain 3, splice variant 2, topological domain 2, signal peptide 1, chain 1, sequence variant 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86UP6-F1	79.43	0.46

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (5): 17–58, 85–107, 154–180, 207–229, 442–498

Glycosylation sites (5): 67, 394, 419, 29, 57

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 70 (showing top): GOCC_SECRETORY_GRANULE, GOCC_CELL_SURFACE, GOBP_PROTEIN_MATURATION, GRE_C, TGACATY_UNKNOWN, GOBP_ZYMOGEN_ACTIVATION, GOCC_ZYMOGEN_GRANULE, GOCC_SECRETORY_VESICLE, GOBP_CELL_DIVISION, GOCC_SECRETORY_GRANULE_MEMBRANE, GOBP_PROTEOLYSIS, GEORGES_TARGETS_OF_MIR192_AND_MIR215, YOSHIMURA_MAPK8_TARGETS_UP, GOBP_PROTEIN_PROCESSING, MAFG_TARGET_GENES

GO Biological Process (3): cell adhesion (GO:0007155), trypsinogen activation (GO:0032023), cell division (GO:0051301)

GO Molecular Function (0):

GO Cellular Component (6): obsolete extracellular space (GO:0005615), cell surface (GO:0009986), membrane (GO:0016020), zymogen granule membrane (GO:0042589), cytoplasmic vesicle (GO:0031410), zymogen granule (GO:0042588)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular process	2
cellular anatomical structure	2
zymogen activation	1
secretory granule membrane	1
zymogen granule	1
cytoplasm	1
intracellular vesicle	1
secretory granule	1

Protein interactions and networks

STRING

764 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CUZD1	ZPLD1	Q8TCW7	518
CUZD1	SYCN	Q0VAF6	455
CUZD1	RNF222	A6NCQ9	432
CUZD1	A0A087WTP8	A0A087WTP8	396
CUZD1	CELA2B	P08218	386
CUZD1	CELA3A	P09093	384
CUZD1	CPB1	P15086	383
CUZD1	CELA2A	P08217	382
CUZD1	MYADML2	A6NDP7	365
CUZD1	ZCCHC18	P0CG32	317
CUZD1	ERP27	Q96DN0	314
CUZD1	AGAP4	Q96P64	312
CUZD1	LYG2	Q86SG7	310
CUZD1	FAM24B	Q8N5W8	306
CUZD1	GP2	P55259	302

IntAct

2 interactions, top by confidence:

A	B	Type	Score
CUZD1	MYH9	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (2): CUZD1 (Proximity Label-MS), CUZD1 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A2R8Y4Y8, A0A2R8YFL7, A0A2R8YFM6, A0A8J1K1A4, A0A8M9PDM1, A8MZH6, C5IAW9, E2RK30, E9Q9F6, G5E8D7, O54766, O54767, O77726, O88393, P08F94, P0DP43, P20239, P26342, P35054, P42099, P47983, P47984, P48829, P48834, P70412, P83121, Q00193, Q03167, Q05996, Q09276, Q2Q0J1, Q4FZG8, Q4V7E2, Q5SY80, Q62005, Q6DFV8, Q6NXM3, Q6UQ28, Q7T2Z5, Q86UP6

Diamond homologs: A8Q2D1, C6K2K4, C6KFA3, D5FM38, O43897, O57460, P48740, P79953, P97435, P98064, Q4A3R3, Q5E9P5, Q60997, Q62381, Q6F3F9, Q7Z408, Q86SQ4, Q86UP6, Q8BNJ6, Q8BQH6, Q8BU25, Q8BZE1, Q8CHN8, Q8CIZ5, Q8NC67, Q8R4I7, Q8TDF5, Q90WD8, Q923L3, Q95218, Q96PZ7, Q9EQT1, Q9JJS0, Q9NQ36, Q9QZT0, Q9UGM3, Q9W332, A2RUV9, B8VIV4, F1RWC3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

79 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	70
Likely benign	5
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3244863	NC_000010.10:g.(?122842033)(124813281_?)del	Pathogenic

SpliceAI

1479 predictions. Top by Δscore:

Variant	Effect	Δscore
10:122832449:TC:T	acceptor_gain	1.0000
10:122832450:CC:C	acceptor_gain	1.0000
10:122832450:CCTAA:C	acceptor_loss	1.0000
10:122832452:T:C	acceptor_loss	1.0000
10:122833666:TCTTA:T	donor_loss	1.0000
10:122833667:CTTA:C	donor_loss	1.0000
10:122833668:TTAC:T	donor_loss	1.0000
10:122833669:TACCT:T	donor_loss	1.0000
10:122833670:ACC:A	donor_loss	1.0000
10:122834250:CAAAT:C	acceptor_gain	1.0000
10:122834254:T:C	acceptor_gain	1.0000
10:122834254:T:TC	acceptor_gain	1.0000
10:122834705:CCCA:C	donor_gain	1.0000
10:122834709:CT:C	donor_gain	1.0000
10:122835098:C:CA	acceptor_loss	1.0000
10:122835099:T:C	acceptor_loss	1.0000
10:122836829:A:AC	donor_gain	1.0000
10:122836830:C:CC	donor_gain	1.0000
10:122837402:A:AC	donor_gain	1.0000
10:122837403:C:CC	donor_gain	1.0000
10:122832448:ATC:A	acceptor_gain	0.9900
10:122832451:C:CC	acceptor_gain	0.9900
10:122832451:C:T	acceptor_gain	0.9900
10:122832457:T:C	acceptor_gain	0.9900
10:122832457:T:TC	acceptor_gain	0.9900
10:122833670:A:AC	donor_gain	0.9900
10:122833671:C:CC	donor_gain	0.9900
10:122833936:TACAT:T	acceptor_gain	0.9900
10:122833938:CAT:C	acceptor_gain	0.9900
10:122833940:TC:T	acceptor_loss	0.9900

AlphaMissense

4011 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:122837457:C:A	W182C	0.997
10:122837457:C:G	W182C	0.997
10:122837502:G:C	S167R	0.997
10:122837502:G:T	S167R	0.997
10:122837504:T:G	S167R	0.997
10:122837459:A:G	W182R	0.995
10:122837459:A:T	W182R	0.995
10:122837463:A:C	C180W	0.995
10:122837464:C:G	C180S	0.995
10:122837465:A:T	C180S	0.995
10:122837464:C:T	C180Y	0.994
10:122837465:A:G	C180R	0.994
10:122836869:G:T	A260D	0.993
10:122837422:A:G	L194P	0.993
10:122836920:A:G	L243P	0.992
10:122837028:C:G	C207S	0.992
10:122837029:A:T	C207S	0.992
10:122836864:A:C	Y262D	0.991
10:122836874:A:C	F258L	0.991
10:122836874:A:T	F258L	0.991
10:122836875:A:G	F258S	0.991
10:122836876:A:G	F258L	0.991
10:122836914:A:T	V245D	0.991
10:122836870:C:G	A260P	0.990
10:122836962:C:G	C229S	0.989
10:122836963:A:T	C229S	0.989
10:122834994:C:G	C365S	0.988
10:122834995:A:T	C365S	0.988
10:122837464:C:A	C180F	0.988
10:122836875:A:C	F258C	0.987

dbSNP variants (sampled 300 via entrez): RS1000391048 (10:122839537 A>C,G), RS1000513793 (10:122842903 C>T), RS1000686731 (10:122832855 C>T), RS1001029812 (10:122846182 A>G), RS1001343549 (10:122833886 T>A,C,G), RS1001740010 (10:122847017 T>C), RS1001766235 (10:122847258 G>A), RS1001838012 (10:122840726 G>A), RS1001974087 (10:122840428 C>T), RS1002083788 (10:122847121 A>C), RS1002086261 (10:122833713 G>A,C), RS1002347922 (10:122835190 T>G), RS1002539780 (10:122846754 A>G), RS1002671270 (10:122835397 C>T), RS1002698172 (10:122841985 G>T)

Disease associations

OMIM: gene MIM:616644 | disease phenotypes: MIM:610006

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (2): 2-methylbutyryl-CoA dehydrogenase deficiency (MONDO:0012392), schizophrenia (MONDO:0005090)

Orphanet (1): 2-methylbutyryl-CoA dehydrogenase deficiency (Orphanet:79157)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C566487	2-Methylbutyryl-CoA Dehydrogenase Deficiency (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, affects cotreatment, increases expression	7
entinostat	affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
methylmercuric chloride	decreases expression, increases expression	1
triphenyl phosphate	affects expression	1
trichostatin A	increases expression, decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
potassium chromate(VI)	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	1
dorsomorphin	affects cotreatment, increases expression, decreases expression	1
Arsenic	affects methylation	1
Methotrexate	increases expression	1
Phenylmercuric Acetate	increases expression, affects cotreatment	1
Quercetin	increases expression	1
Tretinoin	decreases expression	1
Vanadates	increases expression	1
Genistein	increases expression	1
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	1

Clinical trials (associated diseases)

301 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety